Navigation Links
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Date:8/24/2007

MINNEAPOLIS, Aug. 24 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II").

The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral vasculature. The Amplatzer Vascular Plug II is a self- expandable nitinol mesh occlusion device and is designed to be introduced in a minimally invasive fashion through a catheter. The delivery cable that comes pre-attached uses the unique AMPLATZER user interface to enable the physician to more precisely position the device in the targeted blood vessel. Once positioned, the cable is unscrewed and the device is released. The vascular plug II is designed with multiple lobes to facilitate rapid clotting.

"I have used the new Amplatzer Vascular Plug and I found it to be very easy to use and very effective in causing a quick and complete occlusion, said Dr. James F. Benenati, Medical Director of the Peripheral Vascular Lab at the Baptist Cardiac & Vascular Institute in Miami, Florida. "Deployment is easy, radio-opacity is excellent and occlusion is complete and rapid."

The vascular plug two comes in sizes ranging from 3 mm to 22 mm enabling treatment of a wider range of vessel sizes. Unlike competing devices, a single vascular plug II is generally required to occlude the targeted vessel making it a cost and time effective alternative.

"The new vascular plug is an important addition to our family of occlusion devices", said Franck Gougeon, President and CEO of AGA. "The vascular plug is among the fastest growing AGA products and we believe this new model can only help to further accelerate its growth. With more products under development that are specifically targeted for use by interventional specialists that treat peripheral vascular disease, t
'/>"/>

SOURCE AGA Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ollowing the provision of clinical,and scientific ... privately,owned UK company Daval International Li...en informed that its innovative,anti-inflammatory ...esignation for the treatment of Amyotrophic Latera...ou Gehrig,s disease, is the most common form of Mo...
(Date:11/6/2009)...Call/ -- BioSpecifics Technologies Corp. (Nasdaq: ...rst-in-class collagenase-based products, today ann... ended September 30, 2009. ,, "We were extreme...s Arthritis Advisory Committee unanimously recomme...M) for the treatment of Dupuytren,s disease, and w...
(Date:11/6/2009)...e/ -- Calbiotech, Inc. announced today that it has... (SBIR) Phase I contract by the U.S. Army Medical ...agreement, Calbiotech will develop analyte specifi...s. ,, Dengue virus is a mosquito-born flaviv...rces deployed to tropical areas of the world. Due ...
(Date:11/5/2009)...rstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today an...r ended September 30, 2009. GenVec reported a net ...ee months ended September 30, 2009 compared to a n...omparable quarter of 2008. For the nine months end... million ($0.15 per share), compared to a net loss...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
..., , , , Martin Simon, Petra Albrec..., Martin Simon, Petra Albrecht, and Helmut ... Germany, Department of Ecology , Andrs Jar... , With the help of the Eppendorf cMaste... expression of Paramecium primaurelia individual c...
..., , , , George Halley and Vincent ...5 Prime, Inc., Boulder, CO, USA , Vincent P...ion Lab, Westbury, , NY , , ...ve become very popular because of their convenienc...ic amplification. Typical Hot Start , enz...
..., , , , Abstract , , ...ws researchers to determine , the presence,...script in , the organism, tissue or cell of... synthesis of a cDNA copy of all the mRNA present... of the gene(s) of interest. Due to buffer incompa...
Other Biology Technology:Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 2Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 3Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 4Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 5Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 6Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf , cMaster RTplusPCR System 7HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 2HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 3HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 4HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 5HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 6HotMasterAn innovative Hot Start/Cold Stop technology for better , PCR* results 7cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 2cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 3cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 4cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 6
(Date:11/8/2009)...loss of a gene through deletion of genetic materia...abnormalities in learning and behavior, said a con...dicine ( www.bcm.edu ) in a report that appears on...This research goes about 95 percent of the way to ...viduals to this gene," said Dr. Arthur L. Beaudet ...
(Date:11/6/2009)... in harmony with their arboreal hosts. But new res...their trees of choice, the ants can get destructiv...d in the November issue of the American Naturalis...ive trees, and it reopens a centuries-old debate o...ts and certain species of plants and trees have co...
(Date:11/5/2009)...le University have developed synthetic molecules c...HIV and HIV-infected cells, as well as to prostate... the Journal of the American Chemical Society , c...e diseases. , The molecules called "antibody-r...ibody-recruiting molecule targeting prostate cance...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Ants are friendly to some trees, but not others 2New synthetic molecules trigger immune response to HIV and prostate cancer 21 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 11 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 21 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 3Wildfires set to increase 50 percent by 2050 9392 1Wildfires set to increase 50 percent by 2050 9392 2More Can Be Done to Slow Obesitys Toll on Health 3A Experts 52960 1More Can Be Done to Slow Obesitys Toll on Health 3A Experts 52960 2More Can Be Done to Slow Obesitys Toll on Health 3A Experts 52960 3More Can Be Done to Slow Obesitys Toll on Health 3A Experts 52960 4
...ing plastic waste, discarded lead-acid batteries a...ed attack under a new agreement signed by the Unit...al treaty body controlling hazardous wastes. The M...irobi, Kenya, by the UN Environment Programme (UNE...the Basel Convention on the Control of Transbounda...
...gene they suspect plays an important role in trigg...rops a century-and-a-half ago. , And the pathogen...nts of agricultural damage throughout the modern w.... , The scientists describe the gene, called Avr3...tion of the Proceedings of the National Academy of...
...oute of drug administration to improve patient com... skin patches are rapidly becoming an important he...arket share for the treatment of chronic condition...logy is set to make further inroads as transdermal...ay through the development and clinical trial proc...
Other Biology News:Researchers find gene that may be at root of potato blight 2Researchers find gene that may be at root of potato blight 3
Chaperone Sampler Kit from BD Biosciences Pharmingen
SH3 Proteins II Sampler Kit from BD Biosciences Pharmingen
Mouse Anti-SOCS3 Monoclonal Antibody, Unconjugated, Clone SOC-25 from BioLegend
Caveolin Sampler Kit from BD Biosciences Pharmingen
Biology Products: